Background. There are limited data on outcomes of HIVinfected, drug-resistant tuberculosis (DR-TB) patients who are on antiretroviral therapy (ART). We compared outcomes among HIV-infected and -uninfected patients treated for DR-TB in Khayelitsha, South Africa. Methods. Routine data of patients diagnosed with DR-TB in Khayelitsha from January 2008 to December 2011 were analysed retrospectively. Outcomes until December 2013 were included. Results. A total of 875 patients were diagnosed with DR-TB. Overall, 607 (69%) were HIV-positive, 232 (27%) HIV-negative, with status unknown in 36 (4%). Among HIV-positive patients, 96 (16%) had pre-and extensively drug-resistant TB (XDR-TB), 373 (61%) had multidrugThe top nine best abstracts from the biennial Southern African HIV Clinicians Society Conference, held in September 2014, are provided here. Presentations from the conference may be viewed online: http://sahivsoc2014.co.za/2014-speaker-presentations/ resistant TB (MDR-TB), 129 (21%) had rifampicin monoresistance, and 9 (1%) had presumed DR-TB. Among the HIV-positive patients, 34 (15%) had pre-and XDR-TB, 144 (62%) had MDR-TB, 28 (12%) had rifampicin monoresistance and 26 (11%) had presumed DR-TB. A total of 139 (16%) patients did not start DR-TB treatment; 64/139 (46%) died before treatment initiation (55 HIV-positive, 7 HIVnegative; p<0.001). Among those who started DR-TB treatment, 507/736 (69%) were HIV-positive. Of these 507 patients, 470 (93%) were on ART, with 236 (47%) already on ART at DR-TB diagnosis; median CD4 + count was 120 cells/mm 3 (interquartile range 55 -250). Among those with final outcomes (642), treatment was successful in 213/440 (48%) and 88/189 (47%) of HIV-positive and HIV-negative patients, respectively. More HIV-negative patients were lost from treatment (LFT) (37% HIV-negative v. 27% HIV-positive, p=0.01). Mortality was greater among HIV-positive patients (18% HIVpositive v. 9% HIV-negative, p=0.004) during treatment. There was no difference in treatment failure: 26/440 (6%) HIV-positive and 14/189 (7%) HIV-negative patients failed treatment (p>0.05). Patients who subsequently died included 31/120 HIV-positive and 15/70 HIVnegative patients who were LFT, and 21/26 HIV-positive and 7/14 HIV-negative patients with treatment failure. There was no significant difference in overall mortality: 19/100 person-years (95% confidence interval (CI) 16 -22) HIV-positive; 17/100 person-years (95% CI 12 -22) HIV-negative; incidence rate ratio 1.14 (95% CI 0.80 -1.67). Conclusions. In the presence of ART, treatment success, treatment failure and long-term mortality were similar in HIV-positive and HIVnegative DR-TB patients. HIV-positive patients on ART experienced greater mortality prior to and during DR-TB treatment. LFT masked mortality in both HIV-positive and HIV-negative patients, with more LFT among HIV-negative patients and 20% mortality thereafter. More effective treatment regimens and strategies for reducing LFT are needed to reduce mortality in DR-TB patients.
A case series of antiretroviral therapy-associated gynaecomastia C Njuguna-Obwolo,* A Uys, B Chisholm, M Blockman, G Maartens, K Cohen, A Swart University of Cape Town *cw.njuguna@uct.ac.za Category: Antiretroviral Treatment Background. Gynaecomastia is associated with antiretroviral therapy (ART). There are few data about the clinical characteristics of patients with ART-associated gynaecomastia and optimal management of this adverse drug reaction (ADR). The National HIV and TB hotline at the Medicines Information Centre offers the following standard advice for ART-associated gynaecomastia: measure free testosterone to exclude hypoandrogenism and substitute efavirenz. Objective. To describe the clinical characteristics, management and clinical outcomes of reported gynaecomastia cases. Methods. We identified all cases of gynaecomastia in HIV-infected patients on ART reported to the hotline between June 2013 and Jan 2014. We collected data on actions taken and clinical outcomes. Results. Twenty-nine suspected gynaecomastia cases were reported, representing 11% (29/274) of total ADR queries received during this period. All were on efavirenz-based regimens, and median age was 33 years (interquartile range (IQR) 17-40). The median onset of gynaecomastia post efavirenz initiation was 19 months (range 2 -99). Twelve patients (41%) had bilateral gynaecomastia, 8 (28%) had unilateral gynaecomastia and 9 (31%) were unknown. Five (17%) patients were on additional drugs associated with gynaecomastia: 1 on amlodipine and 4 on isoniazid. We obtained follow-up information on 21 (72%) patients, with a median follow-up of 62 days (IQR 39 -97). Free serum testosterone was performed in 13 of 21 patients; 11 had normal testosterone and 2 were unknown. Of patients with followup, 18 substituted efavirenz, of whom 4 (22%) improved, 1 (5%) deteriorated, 5 (28%) remained unchanged and 8 (44%) had unknown status. Among patients continuing efavirenz (n=3), 2 were unchanged and 1 had unknown status. Conclusion. Efavirenz-associated gynaecomastia was frequently reported to the hotline. Improvement of gynaecomastia after substitution was variable, and since efavirenz is a component of the preferred firstline ART regimen, more evidence to guide optimal management of this ADR is needed. Usefulness of free testosterone level testing requires further study. Background. In the South African public sector, 11% of patients failing second-line protease inhibitor (PI)-based antiretroviral therapy (ART) have PI resistance. We explored predictors of PI resistance in patients on second-line ART in a private sector cohort from 2004 to 2013. Methods. We categorised patients as having PI resistance if their genotype included ≥1 major resistance mutations to their current PI. We constructed a multivariate logistic regression model, including age, sex, PI duration, adherence by pharmacy claims for 4 months prior to resistance test, and viral load (VL) closest to resistance test. Results. There were 339 patients with at least 4 months of secondline PI-based ART. Mean age was 42 (standard deviation 8) years, 211 (62%) were female, and 309 (91%) were on lopinavir and 30 (9%) on atazanavir. There were ≥ 1 major PI-resistance mutations in 147/339 (43%). Median duration on PI-based ART before genotype was 2.5 years (interquartile range (IQR) 1.4 -4.4). Median VL before genotyping was 85 586 copies/mL (IQR 18 893 -242 103). Having a major PI-resistance mutation was independently associated with age (odds ratio (OR) for 10-year age increase 2.0, 95% CI 1.4 -2.8), highest quartile of ART duration (OR 2.7, 95% CI 1.4 -5.3), and with the highest three adherence quartiles (OR 2.1, 95% CI 1.0 -4.3; OR 2.4, 95% CI 1.1 -4.9; OR 2.6, 95% CI 1.3 -5.2 for 66 -93%, 94 -98% and 99 -100% adherence, respectively). Sex and VL at the time of resistance testing were not associated with PI resistance. Conclusion. In this private sector cohort, the proportion with PI resistance was higher than in public sector studies, which may reflect a longer duration of second-line ART. These results suggest that patients with longer duration of PI-based ART or adherence >65% may be most likely to benefit from genotyping. Background. Adolescence is an important age group for HIV care and treatment programmes, as adolescents have a high rate of HIV acquisition, and perinatally infected children are transitioning into adolescence. Relatively little data comparing gender differences in adolescent ART outcomes in low-income settings are available. Objectives. To investigate gender differences in baseline characteristics and antiretroviral therapy (ART) outcomes in a large multicentre cohort in South Africa (SA). Methods. Routine clinical data from 82 public ART facilities in four provinces in SA were analysed. ART-naive adolescents (ages 9 -19 years) starting ART between 2004 and 2011 were included. The outcomes were: mortality, loss to follow-up (LTFU), viral suppression (<400 copies/mL) and virological failure (two consecutive viral loads >1 000 copies/mL) after starting ART. Competing risks regression and generalised estimating equations were used to analyse outcomes controlling for individual and site-level confounding. Results. A total of 3 175 adolescents were included, of whom 2 123 (66.9%) were adolescent girls. Pregnancy among girls who started ART increased progressively over time, and reached 25.3% by 2011. The median baseline CD4 + cell count of pregnant girls was substantially higher than for non-pregnant girls (205 v. 143 cells/µL; p=0.0001) . LTFU was substantially higher in pregnant girls, adjusted subhazard ratio=1.94 (95% confidence interval (CI) 1.03 -3.65; p<0.040). Viral suppression on ART was lower in pregnant girls, adjusted odds ratio=0.58 (95% CI 0.39 -0.86; p=0.006). Confirmed virological failure was substantially increased among pregnant girls, adjusted hazard ratio=4.85 (95% CI 1.78 -13.1; p=0.002). Conclusion. There were high levels of pregnancy among adolescent girls who started ART, and they had less-advanced HIV disease, likely owing to earlier diagnosis at maternal facilities. However, pregnant girls had increased LTFU and poorer virological outcomes. Programmes to reduce adolescent pregnancy and increased ART adherence support for pregnant adolescents may be important interventions to improve outcomes of adolescents and to reduce vertical HIV transmission. Objectives. To analyse loss to follow-up (LTFU), retention on antiretroviral treatment (ART), viral load (VL) suppression and increase in CD4 + counts on adult patients in the South African public sector national ART programme. Methods. This was a cohort study including all patients who started ART in the South African public sector facilities from 2004 to 2013. ART data were collected routinely through the National TIER.Net database and exported to the District Health Information System (DHIS) in the form of excel pivot table workbooks. National analysis of data by financial years was conducted to determine improvements in retention on ART, CD4 
Determinants of resistance to second-line protease inhibitor-based antiretroviral therapy in the southern

ABSTRACTS
Gender differences and the effect of pregnancy on antiretroviral treatment outcomes amongst adolescents in South Africa
HIV is the primary exclusion criterion in a PrePex
